Table 4.
Clinical characteristics and treatment regimen of patients when they first reached remissiona
| LORA (N=254) |
YORA (N=405) |
P-value | |
|---|---|---|---|
| DAS28 components | |||
| Tender joint count, mean (SD) | 0.6 (1.3) | 0.5 (1.0) | 0.1422 |
| Swollen joint count, mean (SD) | 0.9 (1.5) | 0.8 (1.5) | 0.6349 |
| ESR, mean (SD) | 10.2 (8.8) | 7.8 (0.4) | 0.3834 |
| CRP, mean (SD) | 4.4 (9.2) | 3.9 (5.9) | 0.4824 |
| Patient global assessment, mean (SD) | 2.0 (1.8) | 2.2 (2.0) | 0.3465 |
| Physician global assessment, mean (SD) | 1.3 (1.3) | 1.4 (1.3) | 0.3611 |
| HAQ | |||
| HAQ-DI mean (SD) | 0.8 (0.7) | 0.6 (0.7) | 0.0281 |
| HAQ pain mean (SD) | 0.8 (0.8) | 0.9 (0.8) | 0.0450 |
| DMARD regimen | 0.0039 | ||
| Biologic or JAK inhibitor with or without csDMARD | 41 (16%) | 110 (27%) | |
| Combination csDMARD | 115 (45%) | 169 (42%) | |
| csDMARD monotherapy | 86 (34%) | 110 (27%) | |
| Other RA treatment | |||
| NSAIDS | 44 (17%) | 90 (22%) | 0.1283 |
| Oral glucocorticoid | 68 (27%) | 51 (13%) | <.0001 |
| Mean (SD) dose of prednisone mg/day | 10.2 (9.3) | 8.3 (7.6) | 0.2347 |
CRP C-reactive protein, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire, HAQ-DI health assessment questionnaire disability index, NSAID non-steroidal anti-inflammatory drug, RA rheumatoid arthritis, SD standard deviation
aThe numbers describe N (%) unless specified otherwise